8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 3, 2026·SEC
Aurinia Pharmaceuticals Inc.(AUPH)Earnings, Financials & Key Ratios
AUPH•NASDAQ
8.0× P/E·Price updated Jun 19, 2026
AboutAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Show more
- Revenue$283M+20.4%
- EBITDA$114M+673.7%
- Net Income$287M+4893.1%
- EPS (Diluted)2.07+5167.2%
- Gross Margin88.46%+0.5%
- EBITDA Margin40.34%+542.7%
- Operating Margin37.06%+1959.5%
- Net Margin101.47%+4047.7%
- ROE59.91%+3834.1%
AUPH Key Insights
Aurinia Pharmaceuticals Inc. (AUPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 47.8% free cash flow margin
- ✓Strong 5Y sales CAGR of 41.4%
- ✓Share count reduced 5.1% through buybacks
- ✓Trading near 52-week high
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AUPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AUPH Price & Volume
Aurinia Pharmaceuticals Inc. (AUPH) stock price & volume — 10-year historical chart
Loading chart...
AUPH Growth Metrics
Aurinia Pharmaceuticals Inc. (AUPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years103.27%
5 Years41.38%
3 Years28.3%
TTM20.62%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM648.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM675.58%
Return on Capital
10 Years-26.72%
5 Years-13.06%
3 Years-0.87%
Last Year18.89%
AUPH Recent Earnings
Aurinia Pharmaceuticals Inc. (AUPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.25+38.9%
$0.18
Rev
$78M+0.9%
$77M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.26+23.8%
$0.21
Rev
$77M+3.2%
$75M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.23+43.8%
$0.16
Rev
$73M-1.6%
$75M
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.16-5.9%
$0.17
Rev
$70M+3.4%
$68M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.25vs $0.18+38.9% | $78Mvs $77M+0.9% |
| Q1 2026 | Feb 26, 2026 | $0.26vs $0.21+23.8% | $77Mvs $75M+3.2% |
| Q4 2025 | Nov 4, 2025 | $0.23vs $0.16+43.8% | $73Mvs $75M-1.6% |
| Q3 2025 | Jul 31, 2025 | $0.16vs $0.17-5.9% | $70Mvs $68M+3.4% |
Based on last 12 quarters of dataView full earnings history →
AUPH Peer Comparison
Aurinia Pharmaceuticals Inc. (AUPH) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LGND | 5.51B | 274.88 | 44.84 | 60.4% | 55.95% | 16.19% | 0.44 | |
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 CORT | 8.58B | 79.91 | 97.45 | 12.79% | 6.23% | 7.5% | 0.01 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 |
Compare AUPH vs Peers
Aurinia Pharmaceuticals Inc. (AUPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AUPH Income Statement
Aurinia Pharmaceuticals Inc. (AUPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 420K | 463K | 318K | 50.12M | 45.6M | 134.03M | 175.51M | 235.13M | 283.06M | 298.3M |
Revenue Growth % | 142.77% | 10.24% | -31.32% | 15660.38% | -9% | 193.89% | 30.95% | 33.97% | 20.38% | 20.62% |
Cost of Goods Sold | 1K | 41.38M | 0 | 0 | 1.09M | 5.66M | 14.15M | 28.25M | 32.66M | 30.6M |
COGS % of Revenue | 0.24% | 8937.8% | - | - | 2.39% | 4.23% | 8.06% | 12.01% | 11.54% | - |
Gross Profit | 419K▲ 0% | -40.92M▼ 9865.9% | 318K▲ 100.8% | 50.12M▲ 15660.4% | 44.51M▼ 11.2% | 128.37M▲ 188.4% | 161.37M▲ 25.7% | 206.88M▲ 28.2% | 250.39M▲ 21.0% | 267.7M▲ 0% |
Gross Margin % | 99.76% | -8837.8% | 100% | 100% | 97.61% | 95.77% | 91.94% | 87.99% | 88.46% | 89.74% |
Gross Profit Growth % | 147.93% | -9865.87% | 100.78% | 15660.38% | -11.18% | 188.37% | 25.71% | 28.21% | 21.03% | - |
Operating Expenses | 47.48M | 56.62M | 91.26M | 154.41M | 225.25M | 239.84M | 253.06M | 211.57M | 145.48M | 143.21M |
OpEx % of Revenue | 11305.24% | 12229.16% | 28698.43% | 308.09% | 493.91% | 178.94% | 144.18% | 89.98% | 51.4% | - |
Selling, General & Admin | 12.1M | 13.67M | 22.34M | 97.27M | 171.44M | 196.37M | 195.04M | 172.03M | 101.79M | 103.48M |
SG&A % of Revenue | 2880% | 2953.35% | 7024.53% | 194.09% | 375.92% | 146.51% | 111.12% | 73.16% | 35.96% | - |
Research & Development | 33.93M | 41.38M | 52.87M | 50.33M | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M | 34.23M |
R&D % of Revenue | 8078.57% | 8937.8% | 16624.53% | 100.42% | 112.13% | 33.57% | 28.28% | 8.84% | 11.48% | - |
Other Operating Expenses | 195K | 2.06M | 16.06M | 6.81M | 2.67M | -1.52M | 8.38M | 18.76M | 11.18M | 881K |
Operating Income | -47.06M▲ 0% | -56.16M▼ 19.3% | -90.94M▼ 61.9% | -104.29M▼ 14.7% | -180.74M▼ 73.3% | -111.47M▲ 38.3% | -91.69M▲ 17.7% | -4.69M▲ 94.9% | 104.91M▲ 2338.4% | 124.49M▲ 0% |
Operating Margin % | -11205.48% | -12129.16% | -28598.43% | -208.09% | -396.31% | -83.17% | -52.24% | -1.99% | 37.06% | 41.73% |
Operating Income Growth % | -106.29% | -19.33% | -61.94% | -14.68% | -73.3% | 38.32% | 17.74% | 94.89% | 2338.4% | - |
EBITDA | -45.61M | -54.59M | -89.77M | -102.92M | -177.97M | -108.76M | -80.04M | 14.76M | 114.18M | 143.9M |
EBITDA Margin % | -10858.81% | -11791.14% | -28230.19% | -205.35% | -390.25% | -81.15% | -45.61% | 6.28% | 40.34% | 48.24% |
EBITDA Growth % | -113.77% | -19.7% | -64.44% | -14.64% | -72.93% | 38.89% | 26.41% | 118.44% | 673.71% | 188.56% |
D&A (Non-Cash Add-back) | 1.46M | 1.56M | 1.17M | 1.37M | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M | 19.41M |
EBIT | -47.06M | -55.91M | -90.94M | -104.29M | -180.21M | -106.35M | -74.69M | 12.28M | 118.49M | 142.38M |
Net Interest Income | 1.04M | 2.23M | 2.7M | 1.52M | 529K | 5.12M | 14.22M | 12.13M | 9.24M | 4.88M |
Interest Income | 1.04M | 2.23M | 2.7M | 1.52M | 529K | 5.12M | 17M | 16.97M | 13.57M | 13.52M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 2.77M | 4.83M | 4.33M | 8.64M |
Other Income/Expense | -23.73M | 2.23M | 2.7M | 1.52M | 529K | 5.12M | 14.22M | 12.13M | 9.24M | 9.24M |
Pretax Income | -70.79M▲ 0% | -64.05M▲ 9.5% | -88.24M▼ 37.8% | -102.77M▼ 16.5% | -180.21M▼ 75.3% | -106.35M▲ 41.0% | -77.47M▲ 27.2% | 7.45M▲ 109.6% | 114.16M▲ 1432.7% | 133.73M▲ 0% |
Pretax Margin % | -16855.24% | -13833.05% | -27748.74% | -205.06% | -395.15% | -79.35% | -44.14% | 3.17% | 40.33% | 44.83% |
Income Tax | 0 | 73K | 144K | -94K | 760K | 1.83M | 551K | 1.7M | -173.04M | -164.48M |
Effective Tax Rate % | 0% | -0.11% | -0.16% | 0.09% | -0.42% | -1.72% | -0.71% | 22.77% | -151.59% | -122.99% |
Net Income | -70.79M▲ 0% | -64.12M▲ 9.4% | -88.39M▼ 37.8% | -102.68M▼ 16.2% | -180.97M▼ 76.2% | -108.18M▲ 40.2% | -78.02M▲ 27.9% | 5.75M▲ 107.4% | 287.2M▲ 4893.1% | 298.21M▲ 0% |
Net Margin % | -16855.24% | -13848.81% | -27794.03% | -204.88% | -396.81% | -80.71% | -44.45% | 2.45% | 101.47% | 99.97% |
Net Income Growth % | -203.89% | 9.42% | -37.84% | -16.17% | -76.24% | 40.22% | 27.88% | 107.37% | 4893.08% | 648.43% |
Net Income (Continuing) | -70.79M | -64.12M | -88.39M | -102.68M | -180.97M | -108.18M | -78.02M | 5.75M | 287.2M | 298.21M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.92▲ 0% | -0.76▲ 17.4% | -1.33▼ 75.0% | -0.87▲ 34.6% | -1.40▼ 60.9% | -0.76▲ 45.7% | -0.54▲ 28.9% | 0.04▲ 107.3% | 2.07▲ 5167.2% | 2.17▲ 0% |
EPS Growth % | -39.39% | 17.39% | -75% | 34.59% | -60.92% | 45.71% | 28.95% | 107.28% | 5167.18% | 675.58% |
EPS (Basic) | -0.92 | -0.76 | -1.33 | -0.87 | -1.40 | -0.76 | -0.54 | 0.04 | 2.14 | - |
Diluted Shares Outstanding | 76.95M | 84.78M | 93.02M | 118.47M | 129.37M | 141.91M | 143.24M | 146.19M | 138.7M | 137.64M |
Basic Shares Outstanding | 76.92M | 84.78M | 93.02M | 118.47M | 129.37M | 141.91M | 143.24M | 143.06M | 134.37M | 132.38M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AUPH Balance Sheet
Aurinia Pharmaceuticals Inc. (AUPH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 175.25M | 132.85M | 315.14M | 419.43M | 513.32M | 442.54M | 424.8M | 446.6M | 491.97M | 480.24M |
Cash & Short-Term Investments | 173.46M | 125.86M | 306.02M | 398.33M | 466.08M | 389.39M | 350.49M | 358.48M | 398M | 378.78M |
Cash Only | 165.63M | 117.97M | 306.02M | 272.35M | 231.9M | 94.17M | 48.88M | 83.43M | 80.21M | 41.01M |
Short-Term Investments | 7.83M | 7.89M | 0 | 125.98M | 234.18M | 295.22M | 301.61M | 275.04M | 317.78M | 337.77M |
Accounts Receivable | 109K | 217K | 368K | 0 | 15.41M | 13.48M | 24.09M | 36.54M | 41.45M | 49.17M |
Days Sales Outstanding | 94.73 | 171.07 | 422.39 | - | 123.37 | 36.72 | 50.1 | 56.73 | 53.45 | 49.45 |
Inventory | -109K | 0 | 0 | 13.93M | 19.33M | 24.75M | 39.7M | 39.23M | 45.69M | 46.41M |
Days Inventory Outstanding | - | - | - | - | 6.47K | 1.6K | 1.02K | 506.88 | 510.54 | 546.96 |
Other Current Assets | 0 | 0 | 0 | 1.02M | 796K | 1.33M | 1.03M | 1.13M | 6.83M | 5.88M |
Total Non-Current Assets | 14.6M | 13.02M | 9.16M | 44.23M | 30.04M | 28.32M | 123.26M | 104.05M | 259.62M | 243.75M |
Property, Plant & Equipment | 31K | 41K | 93K | 10.28M | 9.8M | 8.56M | 116.57M | 98.87M | 79.57M | 73.15M |
Fixed Asset Turnover | 13.55x | 11.29x | 3.42x | 4.88x | 4.65x | 15.66x | 1.51x | 2.38x | 3.56x | 3.65x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 14.12M | 12.62M | 8.86M | 9.33M | 8.4M | 6.42M | 4.98M | 4.36M | 3.76M | 3.59M |
Long-Term Investments | 0 | 0 | 0 | 24.38M | 0 | 0 | 201K | 0 | 0 | 0 |
Other Non-Current Assets | 448K | 358K | 209K | 247K | 11.84M | 13.34M | 1.52M | 823K | 93K | 93K |
Total Assets | 189.85M▲ 0% | 145.86M▼ 23.2% | 324.3M▲ 122.3% | 463.66M▲ 43.0% | 543.37M▲ 17.2% | 470.86M▼ 13.3% | 548.06M▲ 16.4% | 550.64M▲ 0.5% | 751.59M▲ 36.5% | 724M▲ 0% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.11x | 0.08x | 0.28x | 0.32x | 0.43x | 0.38x | 0.48x |
Asset Growth % | 233.08% | -23.17% | 122.33% | 42.97% | 17.19% | -13.34% | 16.4% | 0.47% | 36.49% | 71.92% |
Total Current Liabilities | 8.15M | 7.26M | 11.29M | 32M | 40.65M | 46.11M | 77.19M | 97.76M | 93.72M | 86.56M |
Accounts Payable | 3.77M | 2.95M | 4.15M | 2.63M | 3.88M | 3.09M | 4.33M | 5.19M | 3.31M | 2.66M |
Days Payables Outstanding | 1000K | 26.03 | - | - | 1.3K | 198.93 | 111.63 | 67.02 | 37.02 | 34.3 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.59M | 18.14M |
Deferred Revenue (Current) | 118K | 118K | 118K | 0 | 190K | 3.15M | 4.81M | 11M | 3.72M | 18.86M |
Other Current Liabilities | 2.22M | 1.92M | 0 | 6.41M | 4.45M | 2.03M | 1.59M | 66.5M | 69.1M | 59.17M |
Current Ratio | 21.50x | 18.30x | 27.90x | 13.11x | 12.63x | 9.60x | 5.50x | 4.57x | 5.25x | 5.55x |
Quick Ratio | 21.52x | 18.30x | 27.90x | 12.67x | 12.15x | 9.06x | 4.99x | 4.17x | 4.76x | 5.01x |
Cash Conversion Cycle | - | - | - | - | 5.29K | 1.43K | 962.8 | 496.58 | 526.98 | 562.11 |
Total Non-Current Liabilities | 15.95M | 26.03M | 14.41M | 23.91M | 23.63M | 19.32M | 92.92M | 75.4M | 76.53M | 69.81M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 57.22M | 50.5M |
Capital Lease Obligations | 0 | 0 | 0 | 7.62M | 7.68M | 7.15M | 82.01M | 64.3M | 0 | 125.46M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15.51M | 25.7M | 14.2M | 16.3M | 15.95M | 12.17M | 10.91M | 11.11M | 19.31M | 19.32M |
Total Liabilities | 24.1M | 33.29M | 25.7M | 55.91M | 64.28M | 65.42M | 170.11M | 173.17M | 170.26M | 156.37M |
Total Debt | 0 | 0 | 0 | 8.41M | 8.74M | 8.09M | 97.61M | 79.37M | 74.81M | 68.64M |
Net Debt | -165.63M | -117.97M | -306.02M | -263.94M | -223.16M | -86.08M | 48.73M | -4.06M | -5.4M | 27.63M |
Debt / Equity | - | - | - | 0.02x | 0.02x | 0.02x | 0.26x | 0.21x | 0.13x | 0.12x |
Debt / EBITDA | - | - | - | - | - | - | - | 5.38x | 0.66x | 0.48x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.28x | -0.05x | 0.19x |
Interest Coverage | - | - | - | - | - | - | -26.92x | 2.54x | 27.36x | 16.47x |
Total Equity | 165.74M▲ 0% | 112.58M▼ 32.1% | 298.6M▲ 165.2% | 407.75M▲ 36.6% | 479.09M▲ 17.5% | 405.44M▼ 15.4% | 377.95M▼ 6.8% | 377.48M▼ 0.1% | 581.33M▲ 54.0% | 567.63M▲ 0% |
Equity Growth % | 361.04% | -32.08% | 165.25% | 36.55% | 17.5% | -15.37% | -6.78% | -0.13% | 54% | 102.33% |
Book Value per Share | 2.15 | 1.33 | 3.21 | 3.44 | 3.70 | 2.86 | 2.64 | 2.58 | 4.19 | 4.12 |
Total Shareholders' Equity | 165.74M | 112.58M | 298.6M | 407.75M | 479.09M | 405.44M | 377.95M | 377.48M | 581.33M | 567.63M |
Common Stock | 499.2M | 504.65M | 746.49M | 944.33M | 1.18B | 1.19B | 1.2B | 1.19B | 1.12B | 1.09B |
Retained Earnings | -351.84M | -415.96M | -472.48M | -575.16M | -756.12M | -864.3M | -942.32M | -936.57M | -649.37M | -615.01M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -883K | -805K | -805K | -805K | -852K | -1.06M | -730K | -647K | -599K | -880K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUPH Cash Flow Statement
Aurinia Pharmaceuticals Inc. (AUPH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -41.17M | -51.61M | -63.59M | -69.86M | -157.69M | -79.53M | -33.46M | 44.39M | 135.66M | 165.82M |
Operating CF Margin % | -9802.14% | -11146.87% | -19995.28% | -139.39% | -345.78% | -59.34% | -19.06% | 18.88% | 47.93% | - |
Operating CF Growth % | -120% | -25.36% | -23.2% | -9.87% | -125.73% | 49.57% | 57.93% | 232.66% | 205.62% | 2792.89% |
Net Income | -70.79M | -64.12M | -88.39M | -102.68M | -180.97M | -108.18M | -78.02M | 5.75M | 287.2M | 298.21M |
Depreciation & Amortization | 1.46M | 1.56M | 1.17M | 1.37M | 2.76M | 2.71M | 11.65M | 19.45M | 9.27M | 17.09M |
Stock-Based Compensation | 4.24M | 6.86M | 7.41M | 17.45M | 31.24M | 32.3M | 45.31M | 31.6M | 14.68M | 10.49M |
Deferred Taxes | 23.99M | 9.97M | 0 | 0 | 0 | 0 | 0 | 0 | -176.19M | -167.29M |
Other Non-Cash Items | -1.77M | 118K | 14.19M | 9.48M | 10.9M | 462K | -6.79M | -17.85M | 9.48M | 1.68M |
Working Capital Changes | 1.7M | -6M | 2.03M | 4.52M | -21.63M | -6.82M | -5.61M | 5.45M | -8.78M | 5.63M |
Change in Receivables | -23K | -108K | -151K | -13.62M | -15.41M | 1.93M | -10.61M | -12.46M | -4.91M | -8.92M |
Change in Inventory | 0 | 0 | 0 | -13.93M | -5.64M | -9.07M | -15.87M | 477K | -6.46M | -143.12K |
Change in Payables | 2.17M | -888K | 0 | 13.62M | 4.08M | -792K | 1.24M | 860K | -1.87M | -412.28K |
Cash from Investing | -8M | -66K | 7.78M | -158.19M | -103.87M | -60.63M | -6.71M | 39.26M | -32.77M | -82.01M |
Capital Expenditures | -25K | -75K | -85K | -7.34M | -1.5M | -292K | -718K | -281K | -252K | -274K |
CapEx % of Revenue | 5.95% | 16.2% | 26.73% | 14.65% | 3.29% | 0.22% | 0.41% | 0.12% | 0.09% | 0.09% |
Acquisitions | 0 | 45K | 0 | 1.76M | -1.2M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -7.98M | -45K | -16K | -1.76M | -16.63M | -663K | -11.86M | -43K | 0 | 0 |
Cash from Financing | 175.15M | 4.01M | 243.85M | 194.38M | 221.11M | 2.43M | -5.13M | -49.09M | -106.11M | -109.08M |
Debt Issued (Net) | 0 | 0 | -127K | 0 | 0 | 0 | -10.03M | -11.99M | -13.14M | -13.9M |
Equity Issued (Net) | 162.32M | 0 | 223.12M | 187.73M | 196.74M | 0 | 0 | -40.24M | -83.21M | -83.96M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40.24M | -98.16M | -86.46M |
Other Financing | 12.83M | 4.01M | 20.86M | 6.64M | 24.37M | 2.43M | 4.89M | 3.14M | -9.76M | -11.23M |
Net Change in Cash | 125.98M▲ 0% | -47.66M▼ 137.8% | 188.05M▲ 494.6% | -33.67M▼ 117.9% | -40.45M▼ 20.1% | -137.73M▼ 240.5% | -45.3M▲ 67.1% | 34.56M▲ 176.3% | -3.22M▼ 109.3% | -25.42M▲ 0% |
Free Cash Flow | -41.19M▲ 0% | -51.69M▼ 25.5% | -63.69M▼ 23.2% | -77.2M▼ 21.2% | -159.19M▼ 106.2% | -79.82M▲ 49.9% | -34.18M▲ 57.2% | 44.11M▲ 229.0% | 135.41M▲ 207.0% | 165.55M▲ 0% |
FCF Margin % | -9808.1% | -11163.07% | -20027.04% | -154.04% | -349.07% | -59.55% | -19.47% | 18.76% | 47.84% | 55.5% |
FCF Growth % | -119.84% | -25.47% | -23.22% | -21.22% | -106.21% | 49.86% | 57.18% | 229.05% | 206.99% | 158.67% |
FCF per Share | -0.54 | -0.61 | -0.68 | -0.65 | -1.23 | -0.56 | -0.24 | 0.30 | 0.98 | 1.20 |
FCF Conversion (FCF/Net Income) | 0.58x | 0.80x | 0.72x | 0.68x | 0.87x | 0.74x | 0.43x | 7.72x | 0.47x | 0.56x |
Interest Paid | 0 | 0 | 59K | 0 | 257K | 1.98M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 257K | 1.98M | 496K | 2.18M | 0 | 1.08M |
AUPH Key Ratios
Aurinia Pharmaceuticals Inc. (AUPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -70.2% | -46.08% | -42.99% | -29.07% | -40.81% | -24.46% | -19.92% | 1.52% | 59.91% | 64.48% |
Return on Invested Capital (ROIC) | - | - | - | -114.7% | -67.82% | -29.06% | -18.44% | -0.88% | 16.58% | 19.59% |
Gross Margin | 99.76% | -8837.8% | 100% | 100% | 97.61% | 95.77% | 91.94% | 87.99% | 88.46% | 89.74% |
Net Margin | -16855.24% | -13848.81% | -27794.03% | -204.88% | -396.81% | -80.71% | -44.45% | 2.45% | 101.47% | 99.97% |
Debt / Equity | - | - | - | 0.02x | 0.02x | 0.02x | 0.26x | 0.21x | 0.13x | 0.12x |
Interest Coverage | - | - | - | - | - | - | -26.92x | 2.54x | 27.36x | 16.47x |
FCF Conversion | 0.58x | 0.80x | 0.72x | 0.68x | 0.87x | 0.74x | 0.43x | 7.72x | 0.47x | 0.56x |
Revenue Growth | 142.77% | 10.24% | -31.32% | 15660.38% | -9% | 193.89% | 30.95% | 33.97% | 20.38% | 20.62% |
Related:AUPH Dividend History·AUPH Revenue History·AUPH Price History·AUPH P/E History·AUPH Financial Ratios·AUPH Institutional Holders
AUPH SEC Filings & Documents
Aurinia Pharmaceuticals Inc. (AUPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
AUPH Frequently Asked Questions
Aurinia Pharmaceuticals Inc. (AUPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aurinia Pharmaceuticals Inc. (AUPH) reported $298.3M in revenue for fiscal year 2025. This represents a 38082% increase from $0.8M in 1998.
Aurinia Pharmaceuticals Inc. (AUPH) grew revenue by 20.4% over the past year. This is strong growth.
Yes, Aurinia Pharmaceuticals Inc. (AUPH) is profitable, generating $298.2M in net income for fiscal year 2025 (101.5% net margin).
Dividend & Returns
Aurinia Pharmaceuticals Inc. (AUPH) has a return on equity (ROE) of 59.9%. This is excellent, indicating efficient use of shareholder capital.
Aurinia Pharmaceuticals Inc. (AUPH) generated $165.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.